To date, several TKIs targeting EGFR, ALK, and ROS1 mutations had shown promising efficacy in treating EGFR-,ALK-,or ROS1- mutated NSCLC patients (60–80% response rate and 10–30 months of PFS). This evidence concerns the gene EGFR and non-small cell lung carcinoma.